Sanofi Holds Off Generic Rivals in Eloxatin Cancer Drug Case

Generic-drug makers seeking permission to market versions of Sanofi-Aventis’ cancer treatment Eloxatin were dealt a setback when a federal appeals court vacated a ruling in their favor. In an expedited review of Sanofi’s appeal, the U.S. Court of Appeals for the Federal Circuit found that Judge Joel Pisano of the U.S. District Court for the District of New Jersey erred when he ruled that defendants, including Sandoz and Teva Pharmaceuticals USA, didn’t infringe claims of the ’874 patent covering Eloxatin (oxaliplatin).
Generic Line